Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis
Serotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into pediatric immunization programs across the globe. This epidemiological finding has generated debate regarding the effectivene...
Gespeichert in:
| Veröffentlicht in: | Vaccine Jg. 37; H. 43; S. 6310 - 6316 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Netherlands
Elsevier Ltd
08.10.2019
Elsevier Limited |
| Schlagworte: | |
| ISSN: | 0264-410X, 1873-2518, 1873-2518 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Serotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into pediatric immunization programs across the globe. This epidemiological finding has generated debate regarding the effectiveness of PCV13 against serotype 3 disease. Evaluating PCV13 effectiveness against serotype 3 is especially critical in adults, where serotype 3 makes up an important amount of remaining pneumococcal disease.
We performed a systematic review of the published literature to assess the direct effectiveness of PCV13 against serotype 3 community-acquired pneumonia (CAP) among adults. We then estimated overall vaccine effectiveness (VE) using a pooled analysis of the individual-level, raw data.
Two published studies met inclusion criteria. One was a randomized controlled trial conducted in the Netherlands and published in 2014. The other was a recently-published case-control study conducted in Louisville, Kentucky that used a test-negative design (TND). We also identified a third TND study conducted in Argentina that was recently presented as a conference abstract but is not yet published. All three studies were conducted in adults aged ≥65 years. PCV13 VE against serotype 3 hospitalized CAP was 52.5% (95%CI: 6.2–75.9%) from the pooled analysis of individual-level data from all three studies. Results were similar if the unpublished estimate was excluded (serotype 3 VE = 53.6% [95%CI: 6.7–76.9%]). No heterogeneity was observed.
Currently-available evidence, although limited to three studies, suggests that PCV13 provides direct protection against serotype 3 hospitalized CAP in adults aged ≥65 years. |
|---|---|
| AbstractList | Serotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into pediatric immunization programs across the globe. This epidemiological finding has generated debate regarding the effectiveness of PCV13 against serotype 3 disease. Evaluating PCV13 effectiveness against serotype 3 is especially critical in adults, where serotype 3 makes up an important amount of remaining pneumococcal disease.
We performed a systematic review of the published literature to assess the direct effectiveness of PCV13 against serotype 3 community-acquired pneumonia (CAP) among adults. We then estimated overall vaccine effectiveness (VE) using a pooled analysis of the individual-level, raw data.
Two published studies met inclusion criteria. One was a randomized controlled trial conducted in the Netherlands and published in 2014. The other was a recently-published case-control study conducted in Louisville, Kentucky that used a test-negative design (TND). We also identified a third TND study conducted in Argentina that was recently presented as a conference abstract but is not yet published. All three studies were conducted in adults aged ≥65 years. PCV13 VE against serotype 3 hospitalized CAP was 52.5% (95%CI: 6.2-75.9%) from the pooled analysis of individual-level data from all three studies. Results were similar if the unpublished estimate was excluded (serotype 3 VE = 53.6% [95%CI: 6.7-76.9%]). No heterogeneity was observed.
Currently-available evidence, although limited to three studies, suggests that PCV13 provides direct protection against serotype 3 hospitalized CAP in adults aged ≥65 years. Serotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into pediatric immunization programs across the globe. This epidemiological finding has generated debate regarding the effectiveness of PCV13 against serotype 3 disease. Evaluating PCV13 effectiveness against serotype 3 is especially critical in adults, where serotype 3 makes up an important amount of remaining pneumococcal disease.We performed a systematic review of the published literature to assess the direct effectiveness of PCV13 against serotype 3 community-acquired pneumonia (CAP) among adults. We then estimated overall vaccine effectiveness (VE) using a pooled analysis of the individual-level, raw data.Two published studies met inclusion criteria. One was a randomized controlled trial conducted in the Netherlands and published in 2014. The other was a recently-published case-control study conducted in Louisville, Kentucky that used a test-negative design (TND). We also identified a third TND study conducted in Argentina that was recently presented as a conference abstract but is not yet published. All three studies were conducted in adults aged ≥65 years. PCV13 VE against serotype 3 hospitalized CAP was 52.5% (95%CI: 6.2–75.9%) from the pooled analysis of individual-level data from all three studies. Results were similar if the unpublished estimate was excluded (serotype 3 VE = 53.6% [95%CI: 6.7–76.9%]). No heterogeneity was observed.Currently-available evidence, although limited to three studies, suggests that PCV13 provides direct protection against serotype 3 hospitalized CAP in adults aged ≥65 years. Serotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into pediatric immunization programs across the globe. This epidemiological finding has generated debate regarding the effectiveness of PCV13 against serotype 3 disease. Evaluating PCV13 effectiveness against serotype 3 is especially critical in adults, where serotype 3 makes up an important amount of remaining pneumococcal disease.BACKGROUNDSerotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into pediatric immunization programs across the globe. This epidemiological finding has generated debate regarding the effectiveness of PCV13 against serotype 3 disease. Evaluating PCV13 effectiveness against serotype 3 is especially critical in adults, where serotype 3 makes up an important amount of remaining pneumococcal disease.We performed a systematic review of the published literature to assess the direct effectiveness of PCV13 against serotype 3 community-acquired pneumonia (CAP) among adults. We then estimated overall vaccine effectiveness (VE) using a pooled analysis of the individual-level, raw data.METHODSWe performed a systematic review of the published literature to assess the direct effectiveness of PCV13 against serotype 3 community-acquired pneumonia (CAP) among adults. We then estimated overall vaccine effectiveness (VE) using a pooled analysis of the individual-level, raw data.Two published studies met inclusion criteria. One was a randomized controlled trial conducted in the Netherlands and published in 2014. The other was a recently-published case-control study conducted in Louisville, Kentucky that used a test-negative design (TND). We also identified a third TND study conducted in Argentina that was recently presented as a conference abstract but is not yet published. All three studies were conducted in adults aged ≥65 years. PCV13 VE against serotype 3 hospitalized CAP was 52.5% (95%CI: 6.2-75.9%) from the pooled analysis of individual-level data from all three studies. Results were similar if the unpublished estimate was excluded (serotype 3 VE = 53.6% [95%CI: 6.7-76.9%]). No heterogeneity was observed.RESULTSTwo published studies met inclusion criteria. One was a randomized controlled trial conducted in the Netherlands and published in 2014. The other was a recently-published case-control study conducted in Louisville, Kentucky that used a test-negative design (TND). We also identified a third TND study conducted in Argentina that was recently presented as a conference abstract but is not yet published. All three studies were conducted in adults aged ≥65 years. PCV13 VE against serotype 3 hospitalized CAP was 52.5% (95%CI: 6.2-75.9%) from the pooled analysis of individual-level data from all three studies. Results were similar if the unpublished estimate was excluded (serotype 3 VE = 53.6% [95%CI: 6.7-76.9%]). No heterogeneity was observed.Currently-available evidence, although limited to three studies, suggests that PCV13 provides direct protection against serotype 3 hospitalized CAP in adults aged ≥65 years.CONCLUSIONSCurrently-available evidence, although limited to three studies, suggests that PCV13 provides direct protection against serotype 3 hospitalized CAP in adults aged ≥65 years. BackgroundSerotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into pediatric immunization programs across the globe. This epidemiological finding has generated debate regarding the effectiveness of PCV13 against serotype 3 disease. Evaluating PCV13 effectiveness against serotype 3 is especially critical in adults, where serotype 3 makes up an important amount of remaining pneumococcal disease.MethodsWe performed a systematic review of the published literature to assess the direct effectiveness of PCV13 against serotype 3 community-acquired pneumonia (CAP) among adults. We then estimated overall vaccine effectiveness (VE) using a pooled analysis of the individual-level, raw data.ResultsTwo published studies met inclusion criteria. One was a randomized controlled trial conducted in the Netherlands and published in 2014. The other was a recently-published case-control study conducted in Louisville, Kentucky that used a test-negative design (TND). We also identified a third TND study conducted in Argentina that was recently presented as a conference abstract but is not yet published. All three studies were conducted in adults aged ≥65 years. PCV13 VE against serotype 3 hospitalized CAP was 52.5% (95%CI: 6.2–75.9%) from the pooled analysis of individual-level data from all three studies. Results were similar if the unpublished estimate was excluded (serotype 3 VE = 53.6% [95%CI: 6.7–76.9%]). No heterogeneity was observed.ConclusionsCurrently-available evidence, although limited to three studies, suggests that PCV13 provides direct protection against serotype 3 hospitalized CAP in adults aged ≥65 years. AbstractBackgroundSerotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into pediatric immunization programs across the globe. This epidemiological finding has generated debate regarding the effectiveness of PCV13 against serotype 3 disease. Evaluating PCV13 effectiveness against serotype 3 is especially critical in adults, where serotype 3 makes up an important amount of remaining pneumococcal disease. MethodsWe performed a systematic review of the published literature to assess the direct effectiveness of PCV13 against serotype 3 community-acquired pneumonia (CAP) among adults. We then estimated overall vaccine effectiveness (VE) using a pooled analysis of the individual-level, raw data. ResultsTwo published studies met inclusion criteria. One was a randomized controlled trial conducted in the Netherlands and published in 2014. The other was a recently-published case-control study conducted in Louisville, Kentucky that used a test-negative design (TND). We also identified a third TND study conducted in Argentina that was recently presented as a conference abstract but is not yet published. All three studies were conducted in adults aged ≥65 years. PCV13 VE against serotype 3 hospitalized CAP was 52.5% (95%CI: 6.2–75.9%) from the pooled analysis of individual-level data from all three studies. Results were similar if the unpublished estimate was excluded (serotype 3 VE = 53.6% [95%CI: 6.7–76.9%]). No heterogeneity was observed. ConclusionsCurrently-available evidence, although limited to three studies, suggests that PCV13 provides direct protection against serotype 3 hospitalized CAP in adults aged ≥65 years. |
| Author | Isturiz, Raul E. Jodar, Luis McLaughlin, John M. Sings, Heather L. Jiang, Qin Gessner, Bradford D. Swerdlow, David L. |
| Author_xml | – sequence: 1 givenname: John M. surname: McLaughlin fullname: McLaughlin, John M. email: john.mclaughlin@pfizer.com – sequence: 2 givenname: Qin surname: Jiang fullname: Jiang, Qin – sequence: 3 givenname: Bradford D. surname: Gessner fullname: Gessner, Bradford D. – sequence: 4 givenname: David L. surname: Swerdlow fullname: Swerdlow, David L. – sequence: 5 givenname: Heather L. surname: Sings fullname: Sings, Heather L. – sequence: 6 givenname: Raul E. surname: Isturiz fullname: Isturiz, Raul E. – sequence: 7 givenname: Luis surname: Jodar fullname: Jodar, Luis |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31522807$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkluLUzEUhYOMOJ3Rn6AEfPGldSfn5FwUlWHwBgMKKvgW0p3dIfU0qUnOSPHPm9qOSEHqUxL41kqy1j5jJz54YuyhgJkA0Txdzm4MovM0kyD6GXQzUP0dNhFdW02lEt0Jm4Bs6mkt4OspO0tpCQCqEv09dloJJWUH7YT9_OhpXAUMiGbgGPxyvDaZ-N6cm2vjfMo8UQx5syZe8fXfit3BO8Od58aOQ07P-AVPm5RpZbJDHunG0Q9uvOXrEAayZWuGTXLpPru7MEOiB_v1nH158_rz5bvp1Ye37y8vrqaoOpmnsq_bSpAyqldyXtkalUAg2TQLbOa9RStQAViF8znYrsVWSYIF1NSruutUdc6e7HzXMXwfKWW9cglpGIynMCYt6xKMaFUtjqOyh-LaNH1BHx-gyzDG8rXfVAOylVVbqEd7apyvyOp1dCsTN_q2gQI83wEYQ0qRFhpdLsEFn6Nxgxagt33rpd5Xord9a-h06buo1YH69oJjulc7HZXcSz9RJ3TkkayLhFnb4I46vDxwwMF5V2biG20o_clC6CQ16E_bWdyOougrISq1jfrFvw3-4wG_AEhC8dc |
| CitedBy_id | crossref_primary_10_1016_j_vaccine_2023_09_043 crossref_primary_10_1093_cid_ciab1051 crossref_primary_10_3390_vaccines9040305 crossref_primary_10_1016_j_vaccine_2022_12_060 crossref_primary_10_1080_14760584_2023_2256394 crossref_primary_10_1164_rccm_202112_2700OC crossref_primary_10_3390_microorganisms11010070 crossref_primary_10_1080_13880209_2021_1872653 crossref_primary_10_1093_cid_ciab066 crossref_primary_10_1007_s40121_021_00406_w crossref_primary_10_1016_j_chpulm_2023_100007 crossref_primary_10_1186_s13643_022_02051_x crossref_primary_10_3390_microorganisms10010127 crossref_primary_10_1099_mgen_0_001196 crossref_primary_10_1002_iid3_70062 crossref_primary_10_1007_s40265_022_01733_z crossref_primary_10_1371_journal_pmed_1003326 crossref_primary_10_1016_j_jmii_2025_01_007 crossref_primary_10_1080_14760584_2021_1984888 crossref_primary_10_1016_j_lanwpc_2023_100815 crossref_primary_10_1080_17843286_2022_2039865 crossref_primary_10_1055_a_2506_4928 crossref_primary_10_2217_fmb_2019_0310 crossref_primary_10_1080_14760584_2021_1889376 crossref_primary_10_1080_14760584_2021_1921579 crossref_primary_10_1093_ofid_ofaf069 crossref_primary_10_1016_j_cmi_2019_10_034 crossref_primary_10_1016_j_vaccine_2024_126543 crossref_primary_10_1080_14737167_2022_2134120 crossref_primary_10_1093_infdis_jiad379 crossref_primary_10_1093_infdis_jiab331 crossref_primary_10_3390_vaccines9020186 crossref_primary_10_1093_cid_ciaa1483 crossref_primary_10_1097_QAI_0000000000002916 crossref_primary_10_1136_bmjresp_2022_001218 crossref_primary_10_1016_j_vaccine_2022_02_081 crossref_primary_10_1080_21645515_2022_2079923 crossref_primary_10_1093_infdis_jiae040 crossref_primary_10_3389_fpubh_2023_1086648 crossref_primary_10_1080_21645515_2025_2518847 crossref_primary_10_1093_cid_ciab307 |
| Cites_doi | 10.2105/AJPH.94.6.958 10.1016/S2213-2600(16)00052-7 10.1016/j.vaccine.2013.02.053 10.1056/NEJMoa1209165 10.1542/peds.113.3.443 10.1016/j.cmi.2017.10.006 10.1017/S0950268814002179 10.1016/j.vaccine.2018.05.097 10.1016/j.vaccine.2017.05.088 10.1097/INF.0000000000000025 10.1093/cid/cit428 10.1542/peds.2008-3099 10.1097/00006454-200112000-00002 10.1016/j.vaccine.2016.10.077 10.1086/431524 10.1586/erv.12.53 10.1136/bmjopen-2017-019034 10.1371/journal.pone.0183191 10.1093/cid/ciy312 10.1371/journal.pone.0161257 10.1016/S1473-3099(18)30052-5 10.1016/S1473-3099(14)70822-9 10.2807/1560-7917.ES2013.18.37.20585 10.1093/ofid/ofy209.021 10.1016/j.vaccine.2017.01.032 10.1016/j.vaccine.2011.09.112 10.1056/NEJMoa022823 10.1128/CVI.00064-12 10.1080/21645515.2018.1538611 10.1001/jama.295.14.1668 10.1056/NEJMoa1408544 10.1016/j.vaccine.2018.01.049 10.1093/infdis/170.2.368 10.1080/21645515.2015.1033600 10.1186/s12879-018-3096-7 10.1001/jama.294.16.2043 10.1016/j.vaccine.2010.04.008 10.1016/j.vaccine.2016.02.043 10.1093/cid/ciu108 10.1016/j.vaccine.2016.06.075 10.1371/journal.ppat.1007438 10.1093/cid/cix647 |
| ContentType | Journal Article |
| Copyright | 2019 The Authors The Authors Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved. 2019. The Authors |
| Copyright_xml | – notice: 2019 The Authors – notice: The Authors – notice: Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved. – notice: 2019. The Authors |
| DBID | 6I. AAFTH AAYXX CITATION NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 |
| DOI | 10.1016/j.vaccine.2019.08.059 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database ProQuest research library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef PubMed Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | PubMed AGRICOLA MEDLINE - Academic Research Library Prep |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: Proquest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 6316 |
| ExternalDocumentID | 31522807 10_1016_j_vaccine_2019_08_059 S0264410X19311351 1_s2_0_S0264410X19311351 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GeographicLocations | United States--US Argentina Netherlands Kentucky |
| GeographicLocations_xml | – name: United States--US – name: Netherlands – name: Kentucky – name: Argentina |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACMHX ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT ADSLC AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGEKW AGGSO AGUBO AGWPP AGYEJ AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- ~HD .GJ 29Q 3V. AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFJKZ AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP 6I. AAFTH 9DU AAYXX AFFHD AGQPQ AIGII CITATION NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 7S9 L.6 |
| ID | FETCH-LOGICAL-c582t-294731e5a5952b3d4c51c0e266fc6b9dcd1c500d5cbb0d87c752e0f04e9548853 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 42 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000491685100012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Thu Oct 02 18:10:24 EDT 2025 Thu Oct 02 06:52:47 EDT 2025 Sat Nov 29 14:22:11 EST 2025 Thu Apr 03 07:07:03 EDT 2025 Sat Nov 29 07:20:11 EST 2025 Tue Nov 18 22:14:20 EST 2025 Tue Dec 03 03:45:15 EST 2024 Tue Feb 25 20:03:34 EST 2025 Tue Oct 14 19:30:27 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 43 |
| Keywords | PCV PCV13 RCT Effectiveness CDC Serotype 3 Pooled analysis PCV10 CI Efficacy MeSH CAPiTA TND mITT VE CAP 13-valent pneumococcal conjugate vaccine (PCV13) Adults Community-acquired pneumonia (CAP) IPD Elderly ECDC invasive pneumococcal disease Centers for Disease Control and Prevention test-negative design Medical Subject Headings vaccine efficacy or effectiveness pneumococcal conjugate vaccine European Centers for Disease Control community-acquired pneumonia Community-acquired Pneumonia Immunization Trial in Adults randomized controlled trial 10-valent pneumococcal conjugate vaccine 13-valent pneumococcal conjugate vaccine confidence interval modified intent-to-treat |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c582t-294731e5a5952b3d4c51c0e266fc6b9dcd1c500d5cbb0d87c752e0f04e9548853 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X19311351 |
| PMID | 31522807 |
| PQID | 2296027237 |
| PQPubID | 105530 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_2400517541 proquest_miscellaneous_2290954669 proquest_journals_2296027237 pubmed_primary_31522807 crossref_citationtrail_10_1016_j_vaccine_2019_08_059 crossref_primary_10_1016_j_vaccine_2019_08_059 elsevier_sciencedirect_doi_10_1016_j_vaccine_2019_08_059 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X19311351 elsevier_clinicalkey_doi_10_1016_j_vaccine_2019_08_059 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-10-08 |
| PublicationDateYYYYMMDD | 2019-10-08 |
| PublicationDate_xml | – month: 10 year: 2019 text: 2019-10-08 day: 08 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Kidlington |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2019 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Lipsitch, Jha, Simonsen (b0235) 2016; 45 Ladhani, Collins, Djennad, Sheppard, Borrow, Fry (b0080) 2018; 18 Accessed July 22nd, 2018. Hanquet, Krizova, Valentiner-Branth, Ladhani, Nuorti, Lepoutre (b0075) 2018 Vila-Corcoles, Ochoa-Gondar, de Diego, Satue, Aragon, Vila-Rovira (b0140) 2018; 18 Prato, Fortunato, Cappelli, Chironna, Martinelli (b0145) 2018; 8 Wortham, Zell, Pondo, Harrison, Schaffner, Lynfield (b0030) 2014; 58 Centers for Disease Control and Prevention Active Bacterial Core Surveillance Emerging Infections Program Network. ABC Report: Streptococcus pneumoniae. 1997–2012. Spicer, Thomas, Holst, Baughman, Farley (b0020) 2014; 33 Centers for Disease Control and Prevention (b0055) 2005; 54 Schwartz, Halloran, Rowhani-Rahbar, Neuzil, Victor (b0110) 2017; 35 Perniciaro S, Van Der Linden M, Imöhl M. Reduced effect of the pediatric pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Germany. 28th ECCMID, Madrid, Spain. 2018;P0586. Pilishvili T. Pneumococcal vaccine effectiveness against invasive disease among adults 65 years or older. Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: US Centers for Disease Control and Prevention (CDC); February 22, 2018. Pilishvili T. 13-valent pneumococcal conjugate vaccine (PCV13) effects on disease caused by serotype 3. Presented at the February 2019 ACIP meeting, Atlanta, GA: Centers for Disease Control and Prevention; 2019. Dagan, Patterson, Juergens, Greenberg, Givon-Lavi, Porat (b0090) 2013; 57 Ramani, Hall, Boulton, Johnson, Zhu (b0045) 2004; 94 Huang, Hinrichsen, Stevenson, Rifas-Shiman, Kleinman, Pelton (b0065) 2009; 124 Pfizer Inc. Response to FDA: STN 125324/1196 (Pfizer data on file). 2015. Haber, An, Foppa, Shay, Ferdinands, Orenstein (b0240) 2015; 143 Sings, De Wals, Gessner, Isturiz, Laferriere, McLaughlin (b0105) 2018 Azarian, Mitchell, Georgieva, Thompson, Ghouila, Pollard (b0280) 2018; 14 McLaughlin, Jiang, Isturiz, Sings, Swerdlow, Gessner (b0150) 2018; 67 Andrews, Waight, Burbidge, Pearce, Roalfe, Zancolli (b0100) 2014; 14 Principi, Esposito (b0260) 2015; 11 Davidson, Parkinson, Bulkow, Fitzgerald, Peters, Parks (b0010) 1994; 170 French, Gordon, Mwalukomo, White, Mwafulirwa, Longwe (b0120) 2016; 28 Pilishvili T, Almendares S, Nanduri S, Warnock R, Wu XW, McKean S, et al. Evaluation of Pneumococcal Vaccines Effectiveness Against Invasive Pneumococcal Disease (IPD) Among U.S. Medicare Beneficiaries ≥65 Years Old. 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Melbourne, Australia; April 2018. Jackson, Nelson (b0250) 2013; 31 Black, Shinefield, Hansen, Elvin, Laufer, Malinoski (b0050) 2001; 20 Pilishvili T. Impact of PCV13 on invasive pneumococcal disease (IPD) Burden and the serotype distribution in U.S. Advisory Committee on Immunization Practices. Atlanta, Georgia: Centers for Disease Control and Prevention; October 24, 2018. McLaughlin, Swerdlow, Isturiz, Jodar (b0180) 2019; 15 Moore MR. Update on effectiveness and impact of PCV13 use among U.S. children. In: Centers for Disease Control and Prevention Active Bacterial Core Surveillance Emergin Infections Program Network, editor. February 26, 2014. Bonten, Huijts, Bolkenbaas, Webber, Patterson, Gault (b0115) 2015; 372 Matanock A. Preliminary Evidence to Recommendations for the Ongoing Review of the PCV13 Recommendation for Adults ≥65 Years Old. Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: US Centers for Disease Control and Prevention (CDC); October 24, 2018. Dominguez, Ciruela, Hernandez, Garcia-Garcia, Soldevila, Izquierdo (b0215) 2017; 12 Goldblatt, Hussain, Andrews, Ashton, Virta, Melegaro (b0265) 2005; 192 Lopardo G, Fridman D, Vizzotti C, Stamboulian D, McLaughlin JM, Jiang Q, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for Community-Acquired Pneumonia in Older Argentinean adults: a test-negative design. Sociedad Argentina de Medicina – XXVI Congreso Nacional de Medicina. Buenos Aires, Argentina; November 2018. Ojal, Hammitt, Gaitho, Scott, Goldblatt (b0255) 2017; 35 Miller, Andrews, Waight, Slack, George (b0205) 2011; 29 Suaya, Jiang, Scott, Gruber, Webber, Schmoele-Thoma (b0135) 2018; 36 van der Linden, Falkenhorst, Perniciaro, Fitzner, Imohl (b0195) 2016; 11 Huijts, Coenjaerts, Bolkenbaas, van Werkhoven, Grobbee, Bonten (b0130) 2018; 24 Gessner, Jiang, Van Werkhoven, Sings, Webber, Scott (b0155) 2019; 37 Webber, Patton, Patterson, Schmoele-Thoma, Huijts, Bonten (b0125) 2017; 35 Moore, Link-Gelles, Schaffner, Lynfield, Holtzman, Harrison (b0210) 2016; 4 De Serres, Skowronski, Wu, Ambrose (b0245) 2013; 18 Lexau, Lynfield, Danila, Pilishvili, Facklam, Farley (b0015) 2005; 294 Poehling, Talbot, Griffin, Craig, Whitney, Zell (b0035) 2006; 295 Kaplan, Mason, Wald, Schutze, Bradley, Tan (b0040) 2004; 113 Weinberger, van der Linden, Imohl, von Kries (b0200) 2016; 34 Simell, Auranen, Kayhty, Goldblatt, Dagan, O'Brien (b0275) 2012; 11 Savulescu, C. PCV13 effectiveness and overall effect of PCV10/13 vaccination programmes in children under five years of age. SpIDnet multicentre studies. ESCAIDE November 2016. 2016; Available from Griffin, Zhu, Moore, Whitney, Grijalva (b0070) 2013; 369 Ramirez, Wiemken, Peyrani, Arnold, Kelley, Mattingly (b0185) 2017; 65 Whitney, Farley, Hadler, Harrison, Bennett, Lynfield (b0025) 2003; 348 Pride, Huijts, Wu, Souza, Passador, Tinder (b0160) 2012; 19 Dagan, Juergens, Trammel, Patterson, Greenberg, Givon-Lavi (b0270) 2016; 34 Kieninger, Kueper, Steul, Juergens, Ahlers, Baker (b0095) 2010; 28 10.1016/j.vaccine.2019.08.059_b0085 10.1016/j.vaccine.2019.08.059_b0285 Miller (10.1016/j.vaccine.2019.08.059_b0205) 2011; 29 Whitney (10.1016/j.vaccine.2019.08.059_b0025) 2003; 348 Davidson (10.1016/j.vaccine.2019.08.059_b0010) 1994; 170 Bonten (10.1016/j.vaccine.2019.08.059_b0115) 2015; 372 Haber (10.1016/j.vaccine.2019.08.059_b0240) 2015; 143 Simell (10.1016/j.vaccine.2019.08.059_b0275) 2012; 11 Ramirez (10.1016/j.vaccine.2019.08.059_b0185) 2017; 65 Ojal (10.1016/j.vaccine.2019.08.059_b0255) 2017; 35 Black (10.1016/j.vaccine.2019.08.059_b0050) 2001; 20 10.1016/j.vaccine.2019.08.059_b0230 10.1016/j.vaccine.2019.08.059_b0190 van der Linden (10.1016/j.vaccine.2019.08.059_b0195) 2016; 11 Kaplan (10.1016/j.vaccine.2019.08.059_b0040) 2004; 113 Webber (10.1016/j.vaccine.2019.08.059_b0125) 2017; 35 Moore (10.1016/j.vaccine.2019.08.059_b0210) 2016; 4 Vila-Corcoles (10.1016/j.vaccine.2019.08.059_b0140) 2018; 18 Griffin (10.1016/j.vaccine.2019.08.059_b0070) 2013; 369 Hanquet (10.1016/j.vaccine.2019.08.059_b0075) 2018 Dagan (10.1016/j.vaccine.2019.08.059_b0090) 2013; 57 McLaughlin (10.1016/j.vaccine.2019.08.059_b0150) 2018; 67 Centers for Disease Control and Prevention (10.1016/j.vaccine.2019.08.059_b0055) 2005; 54 French (10.1016/j.vaccine.2019.08.059_b0120) 2016; 28 Prato (10.1016/j.vaccine.2019.08.059_b0145) 2018; 8 10.1016/j.vaccine.2019.08.059_b0225 De Serres (10.1016/j.vaccine.2019.08.059_b0245) 2013; 18 Azarian (10.1016/j.vaccine.2019.08.059_b0280) 2018; 14 10.1016/j.vaccine.2019.08.059_b0220 Andrews (10.1016/j.vaccine.2019.08.059_b0100) 2014; 14 10.1016/j.vaccine.2019.08.059_b0060 Huang (10.1016/j.vaccine.2019.08.059_b0065) 2009; 124 Jackson (10.1016/j.vaccine.2019.08.059_b0250) 2013; 31 Huijts (10.1016/j.vaccine.2019.08.059_b0130) 2018; 24 Goldblatt (10.1016/j.vaccine.2019.08.059_b0265) 2005; 192 Wortham (10.1016/j.vaccine.2019.08.059_b0030) 2014; 58 Sings (10.1016/j.vaccine.2019.08.059_b0105) 2018 Pride (10.1016/j.vaccine.2019.08.059_b0160) 2012; 19 McLaughlin (10.1016/j.vaccine.2019.08.059_b0180) 2019; 15 Kieninger (10.1016/j.vaccine.2019.08.059_b0095) 2010; 28 Ramani (10.1016/j.vaccine.2019.08.059_b0045) 2004; 94 Principi (10.1016/j.vaccine.2019.08.059_b0260) 2015; 11 Poehling (10.1016/j.vaccine.2019.08.059_b0035) 2006; 295 10.1016/j.vaccine.2019.08.059_b0175 Dominguez (10.1016/j.vaccine.2019.08.059_b0215) 2017; 12 10.1016/j.vaccine.2019.08.059_b0170 Ladhani (10.1016/j.vaccine.2019.08.059_b0080) 2018; 18 Suaya (10.1016/j.vaccine.2019.08.059_b0135) 2018; 36 Dagan (10.1016/j.vaccine.2019.08.059_b0270) 2016; 34 Schwartz (10.1016/j.vaccine.2019.08.059_b0110) 2017; 35 Lexau (10.1016/j.vaccine.2019.08.059_b0015) 2005; 294 Spicer (10.1016/j.vaccine.2019.08.059_b0020) 2014; 33 Weinberger (10.1016/j.vaccine.2019.08.059_b0200) 2016; 34 10.1016/j.vaccine.2019.08.059_b0005 Gessner (10.1016/j.vaccine.2019.08.059_b0155) 2019; 37 10.1016/j.vaccine.2019.08.059_b0165 Lipsitch (10.1016/j.vaccine.2019.08.059_b0235) 2016; 45 |
| References_xml | – reference: Matanock A. Preliminary Evidence to Recommendations for the Ongoing Review of the PCV13 Recommendation for Adults ≥65 Years Old. Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: US Centers for Disease Control and Prevention (CDC); October 24, 2018. – volume: 14 start-page: 839 year: 2014 end-page: 846 ident: b0100 article-title: Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study publication-title: Lancet Infect Dis – volume: 124 start-page: e1 year: 2009 end-page: e11 ident: b0065 article-title: Continued impact of pneumococcal conjugate vaccine on carriage in young children publication-title: Pediatrics – volume: 18 start-page: 196 year: 2018 ident: b0140 article-title: Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study publication-title: BMC Infect Dis – volume: 18 year: 2013 ident: b0245 article-title: The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials publication-title: Euro Surveill – reference: Moore MR. Update on effectiveness and impact of PCV13 use among U.S. children. In: Centers for Disease Control and Prevention Active Bacterial Core Surveillance Emergin Infections Program Network, editor. February 26, 2014. – volume: 24 start-page: 764 year: 2018 end-page: 770 ident: b0130 article-title: The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial publication-title: Clin Microbiol Infection: Off Publ European Soc Clin Microbiol Infect Dis – reference: Savulescu, C. PCV13 effectiveness and overall effect of PCV10/13 vaccination programmes in children under five years of age. SpIDnet multicentre studies. ESCAIDE November 2016. 2016; Available from: – volume: 4 start-page: 399 year: 2016 end-page: 406 ident: b0210 article-title: Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study publication-title: Lancet Respir Med – reference: . Accessed July 22nd, 2018. – volume: 65 start-page: 1806 year: 2017 end-page: 1812 ident: b0185 article-title: Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality publication-title: Clin Infect Dis – volume: 192 start-page: 387 year: 2005 end-page: 393 ident: b0265 article-title: Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study publication-title: J Infect Dis – reference: Pilishvili T. 13-valent pneumococcal conjugate vaccine (PCV13) effects on disease caused by serotype 3. Presented at the February 2019 ACIP meeting, Atlanta, GA: Centers for Disease Control and Prevention; 2019. – volume: 94 start-page: 958 year: 2004 end-page: 959 ident: b0045 article-title: Impact of PCV7 on invasive pneumococcal disease among children younger than 5 years: a population-based study publication-title: Am J Public Health – volume: 28 start-page: 4192 year: 2010 end-page: 4203 ident: b0095 article-title: Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany publication-title: Vaccine – reference: Pilishvili T. Pneumococcal vaccine effectiveness against invasive disease among adults 65 years or older. Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: US Centers for Disease Control and Prevention (CDC); February 22, 2018. – volume: 35 start-page: 4652 year: 2017 end-page: 4657 ident: b0255 article-title: Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: hyporesponsiveness and immune correlates of protection for carriage publication-title: Vaccine – volume: 35 start-page: 184 year: 2017 end-page: 190 ident: b0110 article-title: Rotavirus vaccine effectiveness in low-income settings: an evaluation of the test-negative design publication-title: Vaccine – volume: 54 start-page: 893 year: 2005 end-page: 897 ident: b0055 article-title: Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease–United States, 1998–2003 publication-title: MMWR Morb Mortal Wkly Rep – volume: 12 start-page: e0183191 year: 2017 ident: b0215 article-title: Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7–59 months. A matched case-control study publication-title: PLoS One – reference: Pilishvili T. Impact of PCV13 on invasive pneumococcal disease (IPD) Burden and the serotype distribution in U.S. Advisory Committee on Immunization Practices. Atlanta, Georgia: Centers for Disease Control and Prevention; October 24, 2018. – volume: 57 start-page: 952 year: 2013 end-page: 962 ident: b0090 article-title: Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial publication-title: Clin Infect Dis – volume: 28 start-page: 115 year: 2016 end-page: 122 ident: b0120 article-title: A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults publication-title: Malawi Med J – volume: 29 start-page: 9127 year: 2011 end-page: 9131 ident: b0205 article-title: Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine publication-title: Vaccine – volume: 170 start-page: 368 year: 1994 end-page: 376 ident: b0010 article-title: The epidemiology of invasive pneumococcal disease in Alaska, 1986–1990–ethnic differences and opportunities for prevention publication-title: J Infect Dis – volume: 372 start-page: 1114 year: 2015 end-page: 1125 ident: b0115 article-title: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults publication-title: N Engl J Med – volume: 348 start-page: 1737 year: 2003 end-page: 1746 ident: b0025 article-title: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine publication-title: N Engl J Med – volume: 19 start-page: 1131 year: 2012 end-page: 1141 ident: b0160 article-title: Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine publication-title: Clin Vaccine Immunol – volume: 11 start-page: e0161257 year: 2016 ident: b0195 article-title: Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany publication-title: PLoS ONE – volume: 45 start-page: 2060 year: 2016 end-page: 2074 ident: b0235 article-title: Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies publication-title: Int J Epidemiol – reference: Centers for Disease Control and Prevention Active Bacterial Core Surveillance Emerging Infections Program Network. ABC Report: Streptococcus pneumoniae. 1997–2012. – volume: 294 start-page: 2043 year: 2005 end-page: 2051 ident: b0015 article-title: Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine publication-title: JAMA – volume: 36 start-page: 1477 year: 2018 end-page: 1483 ident: b0135 article-title: Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults publication-title: Vaccine – volume: 33 start-page: 158 year: 2014 end-page: 164 ident: b0020 article-title: Socioeconomic and racial disparities of pediatric invasive pneumococcal disease after the introduction of the 7-valent pneumococcal conjugate vaccine publication-title: Pediatr Infect Dis J – volume: 15 start-page: 584 year: 2019 end-page: 593 ident: b0180 article-title: Decision-making for PCV in adults publication-title: Human Vaccines Immunotherap – reference: Perniciaro S, Van Der Linden M, Imöhl M. Reduced effect of the pediatric pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Germany. 28th ECCMID, Madrid, Spain. 2018;P0586. – volume: 34 start-page: 2062 year: 2016 end-page: 2065 ident: b0200 article-title: Vaccine effectiveness of PCV13 in a 3+1 vaccination schedule publication-title: Vaccine – volume: 35 start-page: 1266 year: 2017 end-page: 1272 ident: b0125 article-title: Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) publication-title: Vaccine – reference: Pilishvili T, Almendares S, Nanduri S, Warnock R, Wu XW, McKean S, et al. Evaluation of Pneumococcal Vaccines Effectiveness Against Invasive Pneumococcal Disease (IPD) Among U.S. Medicare Beneficiaries ≥65 Years Old. 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Melbourne, Australia; April 2018. – volume: 143 start-page: 1417 year: 2015 end-page: 1426 ident: b0240 article-title: A probability model for evaluating the bias and precision of influenza vaccine effectiveness estimates from case-control studies publication-title: Epidemiol Infect – volume: 113 start-page: 443 year: 2004 end-page: 449 ident: b0040 article-title: Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine publication-title: Pediatrics – volume: 20 start-page: 1105 year: 2001 end-page: 1107 ident: b0050 article-title: Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine publication-title: Pediatr Infect Dis J – reference: Lopardo G, Fridman D, Vizzotti C, Stamboulian D, McLaughlin JM, Jiang Q, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for Community-Acquired Pneumonia in Older Argentinean adults: a test-negative design. Sociedad Argentina de Medicina – XXVI Congreso Nacional de Medicina. Buenos Aires, Argentina; November 2018. – volume: 34 start-page: 4313 year: 2016 end-page: 4320 ident: b0270 article-title: Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration publication-title: Vaccine – volume: 295 start-page: 1668 year: 2006 end-page: 1674 ident: b0035 article-title: Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine publication-title: JAMA – year: 2018 ident: b0075 article-title: Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination publication-title: Thorax – volume: 14 start-page: e1007438 year: 2018 ident: b0280 article-title: Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci publication-title: PLoS Pathog – volume: 37 start-page: 5777 year: 2019 end-page: 5787 ident: b0155 article-title: A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands publication-title: Vaccine – volume: 11 start-page: 841 year: 2012 end-page: 855 ident: b0275 article-title: The fundamental link between pneumococcal carriage and disease publication-title: Expert Rev Vaccines – volume: 67 start-page: 1498 year: 2018 end-page: 1506 ident: b0150 article-title: Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for Community-Acquired Pneumonia in Older US Adults: a test-negative design publication-title: Clin Infect Dis – volume: 11 start-page: 1494 year: 2015 end-page: 1500 ident: b0260 article-title: Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines publication-title: Hum Vaccin Immunother – volume: 18 start-page: 441 year: 2018 end-page: 451 ident: b0080 article-title: Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study publication-title: Lancet Infect Dis – volume: 31 start-page: 2165 year: 2013 end-page: 2168 ident: b0250 article-title: The test-negative design for estimating influenza vaccine effectiveness publication-title: Vaccine – year: 2018 ident: b0105 article-title: Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies publication-title: Clin Infect Dis – reference: Pfizer Inc. Response to FDA: STN 125324/1196 (Pfizer data on file). 2015. – volume: 8 start-page: e019034 year: 2018 ident: b0145 article-title: Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year prospective cohort publication-title: BMJ Open – volume: 58 start-page: 1250 year: 2014 end-page: 1257 ident: b0030 article-title: Racial disparities in invasive Streptococcus pneumoniae infections, 1998–2009 publication-title: Clin Infect Dis – volume: 369 start-page: 155 year: 2013 end-page: 163 ident: b0070 article-title: hospitalizations for pneumonia after a decade of pneumococcal vaccination publication-title: N Engl J Med – ident: 10.1016/j.vaccine.2019.08.059_b0085 – volume: 94 start-page: 958 year: 2004 ident: 10.1016/j.vaccine.2019.08.059_b0045 article-title: Impact of PCV7 on invasive pneumococcal disease among children younger than 5 years: a population-based study publication-title: Am J Public Health doi: 10.2105/AJPH.94.6.958 – ident: 10.1016/j.vaccine.2019.08.059_b0165 – ident: 10.1016/j.vaccine.2019.08.059_b0190 – volume: 4 start-page: 399 year: 2016 ident: 10.1016/j.vaccine.2019.08.059_b0210 article-title: Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(16)00052-7 – volume: 31 start-page: 2165 year: 2013 ident: 10.1016/j.vaccine.2019.08.059_b0250 article-title: The test-negative design for estimating influenza vaccine effectiveness publication-title: Vaccine doi: 10.1016/j.vaccine.2013.02.053 – volume: 369 start-page: 155 year: 2013 ident: 10.1016/j.vaccine.2019.08.059_b0070 article-title: hospitalizations for pneumonia after a decade of pneumococcal vaccination publication-title: N Engl J Med doi: 10.1056/NEJMoa1209165 – volume: 113 start-page: 443 year: 2004 ident: 10.1016/j.vaccine.2019.08.059_b0040 article-title: Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine publication-title: Pediatrics doi: 10.1542/peds.113.3.443 – year: 2018 ident: 10.1016/j.vaccine.2019.08.059_b0075 article-title: Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination publication-title: Thorax – volume: 54 start-page: 893 year: 2005 ident: 10.1016/j.vaccine.2019.08.059_b0055 article-title: Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease–United States, 1998–2003 publication-title: MMWR Morb Mortal Wkly Rep – volume: 24 start-page: 764 year: 2018 ident: 10.1016/j.vaccine.2019.08.059_b0130 article-title: The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial publication-title: Clin Microbiol Infection: Off Publ European Soc Clin Microbiol Infect Dis doi: 10.1016/j.cmi.2017.10.006 – volume: 143 start-page: 1417 year: 2015 ident: 10.1016/j.vaccine.2019.08.059_b0240 article-title: A probability model for evaluating the bias and precision of influenza vaccine effectiveness estimates from case-control studies publication-title: Epidemiol Infect doi: 10.1017/S0950268814002179 – volume: 37 start-page: 5777 issue: 38 year: 2019 ident: 10.1016/j.vaccine.2019.08.059_b0155 article-title: A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands publication-title: Vaccine doi: 10.1016/j.vaccine.2018.05.097 – volume: 35 start-page: 4652 year: 2017 ident: 10.1016/j.vaccine.2019.08.059_b0255 article-title: Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: hyporesponsiveness and immune correlates of protection for carriage publication-title: Vaccine doi: 10.1016/j.vaccine.2017.05.088 – volume: 33 start-page: 158 year: 2014 ident: 10.1016/j.vaccine.2019.08.059_b0020 article-title: Socioeconomic and racial disparities of pediatric invasive pneumococcal disease after the introduction of the 7-valent pneumococcal conjugate vaccine publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0000000000000025 – volume: 57 start-page: 952 year: 2013 ident: 10.1016/j.vaccine.2019.08.059_b0090 article-title: Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial publication-title: Clin Infect Dis doi: 10.1093/cid/cit428 – volume: 124 start-page: e1 year: 2009 ident: 10.1016/j.vaccine.2019.08.059_b0065 article-title: Continued impact of pneumococcal conjugate vaccine on carriage in young children publication-title: Pediatrics doi: 10.1542/peds.2008-3099 – volume: 20 start-page: 1105 year: 2001 ident: 10.1016/j.vaccine.2019.08.059_b0050 article-title: Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine publication-title: Pediatr Infect Dis J doi: 10.1097/00006454-200112000-00002 – volume: 35 start-page: 184 year: 2017 ident: 10.1016/j.vaccine.2019.08.059_b0110 article-title: Rotavirus vaccine effectiveness in low-income settings: an evaluation of the test-negative design publication-title: Vaccine doi: 10.1016/j.vaccine.2016.10.077 – volume: 192 start-page: 387 year: 2005 ident: 10.1016/j.vaccine.2019.08.059_b0265 article-title: Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study publication-title: J Infect Dis doi: 10.1086/431524 – volume: 11 start-page: 841 year: 2012 ident: 10.1016/j.vaccine.2019.08.059_b0275 article-title: The fundamental link between pneumococcal carriage and disease publication-title: Expert Rev Vaccines doi: 10.1586/erv.12.53 – volume: 8 start-page: e019034 year: 2018 ident: 10.1016/j.vaccine.2019.08.059_b0145 article-title: Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year prospective cohort publication-title: BMJ Open doi: 10.1136/bmjopen-2017-019034 – volume: 12 start-page: e0183191 year: 2017 ident: 10.1016/j.vaccine.2019.08.059_b0215 article-title: Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7–59 months. A matched case-control study publication-title: PLoS One doi: 10.1371/journal.pone.0183191 – volume: 28 start-page: 115 year: 2016 ident: 10.1016/j.vaccine.2019.08.059_b0120 article-title: A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults publication-title: Malawi Med J – volume: 67 start-page: 1498 year: 2018 ident: 10.1016/j.vaccine.2019.08.059_b0150 article-title: Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for Community-Acquired Pneumonia in Older US Adults: a test-negative design publication-title: Clin Infect Dis doi: 10.1093/cid/ciy312 – volume: 11 start-page: e0161257 year: 2016 ident: 10.1016/j.vaccine.2019.08.059_b0195 article-title: Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany publication-title: PLoS ONE doi: 10.1371/journal.pone.0161257 – volume: 18 start-page: 441 year: 2018 ident: 10.1016/j.vaccine.2019.08.059_b0080 article-title: Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(18)30052-5 – ident: 10.1016/j.vaccine.2019.08.059_b0005 – volume: 14 start-page: 839 year: 2014 ident: 10.1016/j.vaccine.2019.08.059_b0100 article-title: Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(14)70822-9 – volume: 18 year: 2013 ident: 10.1016/j.vaccine.2019.08.059_b0245 article-title: The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials publication-title: Euro Surveill doi: 10.2807/1560-7917.ES2013.18.37.20585 – ident: 10.1016/j.vaccine.2019.08.059_b0060 – ident: 10.1016/j.vaccine.2019.08.059_b0225 doi: 10.1093/ofid/ofy209.021 – volume: 35 start-page: 1266 year: 2017 ident: 10.1016/j.vaccine.2019.08.059_b0125 article-title: Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) publication-title: Vaccine doi: 10.1016/j.vaccine.2017.01.032 – volume: 29 start-page: 9127 year: 2011 ident: 10.1016/j.vaccine.2019.08.059_b0205 article-title: Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine publication-title: Vaccine doi: 10.1016/j.vaccine.2011.09.112 – ident: 10.1016/j.vaccine.2019.08.059_b0230 – year: 2018 ident: 10.1016/j.vaccine.2019.08.059_b0105 article-title: Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies publication-title: Clin Infect Dis – ident: 10.1016/j.vaccine.2019.08.059_b0285 – volume: 45 start-page: 2060 year: 2016 ident: 10.1016/j.vaccine.2019.08.059_b0235 article-title: Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies publication-title: Int J Epidemiol – volume: 348 start-page: 1737 year: 2003 ident: 10.1016/j.vaccine.2019.08.059_b0025 article-title: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa022823 – volume: 19 start-page: 1131 year: 2012 ident: 10.1016/j.vaccine.2019.08.059_b0160 article-title: Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00064-12 – ident: 10.1016/j.vaccine.2019.08.059_b0220 – volume: 15 start-page: 584 issue: 3 year: 2019 ident: 10.1016/j.vaccine.2019.08.059_b0180 article-title: Decision-making for PCV in adults publication-title: Human Vaccines Immunotherap doi: 10.1080/21645515.2018.1538611 – volume: 295 start-page: 1668 year: 2006 ident: 10.1016/j.vaccine.2019.08.059_b0035 article-title: Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine publication-title: JAMA doi: 10.1001/jama.295.14.1668 – volume: 372 start-page: 1114 year: 2015 ident: 10.1016/j.vaccine.2019.08.059_b0115 article-title: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults publication-title: N Engl J Med doi: 10.1056/NEJMoa1408544 – volume: 36 start-page: 1477 year: 2018 ident: 10.1016/j.vaccine.2019.08.059_b0135 article-title: Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults publication-title: Vaccine doi: 10.1016/j.vaccine.2018.01.049 – volume: 170 start-page: 368 year: 1994 ident: 10.1016/j.vaccine.2019.08.059_b0010 article-title: The epidemiology of invasive pneumococcal disease in Alaska, 1986–1990–ethnic differences and opportunities for prevention publication-title: J Infect Dis doi: 10.1093/infdis/170.2.368 – ident: 10.1016/j.vaccine.2019.08.059_b0170 – volume: 11 start-page: 1494 year: 2015 ident: 10.1016/j.vaccine.2019.08.059_b0260 article-title: Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2015.1033600 – volume: 18 start-page: 196 year: 2018 ident: 10.1016/j.vaccine.2019.08.059_b0140 article-title: Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study publication-title: BMC Infect Dis doi: 10.1186/s12879-018-3096-7 – volume: 294 start-page: 2043 year: 2005 ident: 10.1016/j.vaccine.2019.08.059_b0015 article-title: Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine publication-title: JAMA doi: 10.1001/jama.294.16.2043 – volume: 28 start-page: 4192 year: 2010 ident: 10.1016/j.vaccine.2019.08.059_b0095 article-title: Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany publication-title: Vaccine doi: 10.1016/j.vaccine.2010.04.008 – volume: 34 start-page: 2062 year: 2016 ident: 10.1016/j.vaccine.2019.08.059_b0200 article-title: Vaccine effectiveness of PCV13 in a 3+1 vaccination schedule publication-title: Vaccine doi: 10.1016/j.vaccine.2016.02.043 – volume: 58 start-page: 1250 year: 2014 ident: 10.1016/j.vaccine.2019.08.059_b0030 article-title: Racial disparities in invasive Streptococcus pneumoniae infections, 1998–2009 publication-title: Clin Infect Dis doi: 10.1093/cid/ciu108 – volume: 34 start-page: 4313 year: 2016 ident: 10.1016/j.vaccine.2019.08.059_b0270 article-title: Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration publication-title: Vaccine doi: 10.1016/j.vaccine.2016.06.075 – volume: 14 start-page: e1007438 year: 2018 ident: 10.1016/j.vaccine.2019.08.059_b0280 article-title: Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1007438 – ident: 10.1016/j.vaccine.2019.08.059_b0175 – volume: 65 start-page: 1806 year: 2017 ident: 10.1016/j.vaccine.2019.08.059_b0185 article-title: Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality publication-title: Clin Infect Dis doi: 10.1093/cid/cix647 |
| SSID | ssj0005319 |
| Score | 2.4782276 |
| SecondaryResourceType | review_article |
| Snippet | Serotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal conjugate... AbstractBackgroundSerotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent... BackgroundSerotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 6310 |
| SubjectTerms | 13-valent pneumococcal conjugate vaccine (PCV13) Adults Allergy and Immunology Argentina case-control studies Community-acquired pneumonia (CAP) Conjugates Effectiveness Efficacy Elderly Epidemiology Heterogeneity Immunization Kentucky Literature reviews Netherlands Pneumonia Pooled analysis Population decline randomized clinical trials Serotype 3 serotypes Streptococcus infections Streptococcus pneumoniae Studies Systematic review Vaccine efficacy Vaccines |
| Title | Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X19311351 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X19311351 https://dx.doi.org/10.1016/j.vaccine.2019.08.059 https://www.ncbi.nlm.nih.gov/pubmed/31522807 https://www.proquest.com/docview/2296027237 https://www.proquest.com/docview/2290954669 https://www.proquest.com/docview/2400517541 |
| Volume | 37 |
| WOSCitedRecordID | wos000491685100012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIEXJ dateStart: 20091030 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M7P dateStart: 20020101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M0R dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M0T dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7RV dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: Proquest Central customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 8C1 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M2O dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoC4gLj-W1UFZGQj01rWPHccIFlaoVly5RKdXerMR20K4guzS7lSr-PONHNhxKi8RllCgZxXLG48_2zDcIvROZ0qJmLKoyUsMCJY5hzNUqyomhtWBcg54rNiHG42wyyYuw4daGsMrOJzpHrefK7pHvUwpYmwrKxIfFz8hWjbKnq6GExgbasiwJzIXuFX2IB3OFPWCZkURJTCZ9Bs_-bO-yVPbo2kZ35Y7F09KVXj83_Q17ujno-NH_tv4xehjQJz7w5vIE3THNAN3z9SivBuj-SThpH6CdwnNaX-3isz5Fq93FO7jo2a5BZ3BuA2pcVi_u1J-iX0VjVj_m4G3BBjCsuWcru1-HQ3fg8ls5BWCKYQDM7S4wZnjxp4a_aaYlnjbYcYS07_EB7nmnsc-5wWWjsS0TZjRcen6VZ-jr8dHZ4aco1HmIFM_oMqJ5IlhseMlzTiumE8VjBbaSprVKq1wrHStOiOaqqojOhBKcGlKTxFi2OsAbz9FmM2_MS4TBm8C0XCvBVJpUlryOlhmtOdW1qmpTDlHS_WGpAgm6rcXxXXbRbjMZekJaw5C2RifPh2hvrbbwLCC3KaSd-cguxRWcsoR56jZFcZ2iaYNraWUsWyqJ_EIclCUTQOCxLbM4RNlaM6Anj4r-5aPbndXK9Xd6kx2it-vH4HzsiVLZmPnKvQMQPUnT_IZ3EscDxxNo4Qs_etZ9yAA9WjqmVzc34DV6YFvrQy-30ebyYmXeoLvqcjltL0ZoQ5yeWzkRTmYgs8N4hLY-Ho2LU7g7IV6eWUk_j5yX-A05xGlM |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF5V5XnhEV6BAosEPdXteu31AwmhCqhatYkiEarcFnt3jRKBHeqkKOI_8RuZ8frBobRceuCWKB55NZnX7s58HyEvw0jpMPM8J41YBhsU1wWfy5QTM8Oz0BMa5CqyiXA4jCaTeLRGfjWzMNhW2cTEKlDrQuEZ-Q7nUGvzkHvh2_l3B1mj8Ha1odCwZnFoVj9gy1a-OXgP_-8rzvc-jN_tOzWrgKNExBcOj_3Qc41IRCx46mlfCVfByoIgU0Eaa6VdJRjTQqUp01GoQsENy5hvEBstQpYICPlXEFcPWwgHbNy1lHgVkQhsa3zHd9mkmxjamW2fJgqvyrGbLK5QQxEe9exc-Ldat8p5e7f_N23dIbfq6pruWne4S9ZM3iPXLN_mqkeuD-pOgh7ZHFnM7tUWHXcjaOUW3aSjDs0bZHrH2DBUTS3TRvwe-TnKzfJbAdkEbJyqIp8t8TyS1uqnyZdkCoU3BQcv8JSbenT-p4T9kk8TOs1phYFSvqa7tMPVpnamiCa5pkiDZjR8tPgx98mnS9HhA7KeF7l5RChESyg7MhV6KvBTBOfjScQzwXWm0swkfeI3FiVVDfKOXCNfZdPNN5O1JiQaokQOUhH3yXYrNrcoJxcJBI25ymaEF5KOhDx8kWB4lqAp69BZSleWXDL5kVWlOpvADsNFGsk-iVrJujq0Vd-_vHSj8RLZvqdzkT550f4MwRVvzJLcFMvqGdiC-EEQn_OMX-HcCR9W-NB6a6tDD6pjhJt6fP4CnpMb--PBkTw6GB4-ITdx5bbNdIOsL06W5im5qk4X0_LkWRVvKPl82S77G0d2vVA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamARMvXMqtMMBIsKdldew4TpAQmjYqpkFViYH65iW2g1pBUpZ2qOKf8es4tpN2D2PjZQ-8JUqOYjnnZvuc70PopUiUFgVjQZ6QAhYoYQg2V6ggJYYWgnENco5sQgwGyWiUDtfQ77YXxpZVtj7ROWpdKbtH3qMUcm0qKBO9oimLGO73305_BJZByp60tnQaXkUOzeInLN_qNwf78K9fUdp_d7T3PmgYBgLFEzoLaBoJFhqe8ZTTnOlI8VDBKOO4UHGeaqVDxQnRXOU50YlQglNDChIZi5OWWMYIcP_XBAMttl3qe2fKS5gjFYElThREIRmtuod6k53TTNljc1tZljoEUQuVen5c_Fve6-Jf__b_PHN30K0m68a73kzuojVTdtANz8O56KCNj02FQQdtDT2W92IbH61a0-ptvIWHK5RvkOl8sYVErpsZt-L30K9haebfK4gyoPtYVeVkbvcpcfMrcPY1G0NCjsHwK7v7jRmenpXwN-U4w-MSO2yU-jXexSu8bex7jXBWamzp0YyGS48rcx99vpI5fIDWy6o0jxAG_YN0pFCCqTjKLWgfzRJacKoLlRcm66Ko1S6pGvB3y0HyTbZVfhPZzIS0SiktNylPu2hnKTb16CeXCcSt6sq2tReCkYT4fJmgOE_Q1I1LrWUoayqJ_ERcCk9GsPIILb1kFyVLySZr9Nngv3x0s7UYufzOyly66MXyMThde5KWlaaau3dgaRLFcXrBO5HDv-MRjPCht9zlHDLImi0M1eOLB_AcbYClyg8Hg8Mn6KYduK8-3UTrs5O5eYquq9PZuD555lwPRsdXbbF_AIjoxc4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pneumococcal+conjugate+vaccine+against+serotype+3+pneumococcal+pneumonia+in+adults%3A+A+systematic+review+and+pooled+analysis&rft.jtitle=Vaccine&rft.au=McLaughlin%2C+John+M&rft.au=Jiang%2C+Qin&rft.au=Gessner%2C+Bradford+D&rft.au=Swerdlow%2C+David+L&rft.date=2019-10-08&rft.eissn=1873-2518&rft.volume=37&rft.issue=43&rft.spage=6310&rft_id=info:doi/10.1016%2Fj.vaccine.2019.08.059&rft_id=info%3Apmid%2F31522807&rft.externalDocID=31522807 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0264-410X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0264-410X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0264-410X&client=summon |